Short Interest in Exicure, Inc. (NASDAQ:XCUR) Rises By 14.3%

Exicure, Inc. (NASDAQ:XCUR) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 71,837 shares, a growth of 14.3% from the February 12th total of 62,840 shares. Based on an average daily trading volume, of 18,567 shares, the days-to-cover ratio is currently 3.9 days. Currently, 2.4% of the shares of the stock are short sold. Currently, 2.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 18,567 shares, the days-to-cover ratio is currently 3.9 days.

Analysts Set New Price Targets

XCUR has been the subject of a number of recent research reports. Wall Street Zen upgraded Exicure to a “hold” rating in a research report on Saturday, January 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Exicure in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Exicure Stock Up 9.0%

Shares of Exicure stock opened at $4.58 on Tuesday. The stock has a market cap of $29.17 million, a PE ratio of -1.24 and a beta of 4.13. The business has a fifty day simple moving average of $4.60 and a 200 day simple moving average of $4.69. Exicure has a 12 month low of $3.10 and a 12 month high of $15.91.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.